Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Opportunities and Threats of the Legally Facilitated Performance-Based Managed Entry Agreements in Slovakia: The Early-Adoption Perspective

P. Hospodková, K. Gilíková, M. Barták, E. Marušáková, A. Tichopád

. 2023 ; 11 (8) : . [pub] 20230419

Status not-indexed Language English Country Switzerland

Document type Journal Article

Grant support
SGS23/197/OHK5/3T/17 Czech Technical University in Prague

Slovakia has adopted an amendment to Act No. 363/2011, regulating, among other things, drug reimbursement and is undergoing a significant change in the availability of innovative treatments for patients. High expectations are associated with arrangements related to performance-based managed entry agreements. Opinions and positions towards this change appear to be inconsistent, and for the further application of the law in practice and when setting up the main implementation processes, it is necessary to understand the positions and opinions of the individual actors who are involved in the PB-MEA process. The interviews were conducted in the period from 20 May to 15 August 2022 around the same time as the finalisation of the amendment to Act No. 363/2011 and its adoption. A roughly one-hour open interview was conducted on a sample of 12 stakeholders in the following groups: representatives of the Ministry of Health, health-care providers, pharmaceutical companies and others, including a health insurance company. The main objective was to qualitatively describe the perception of this topic by key stakeholders in Slovakia. The responses were analysed using MAXQDATA 2022 software to obtain codes associated with key expressions. We identified three main strong top categories of expressions that strongly dominated the pro-management interviews with stakeholders: legislation, opportunities and threats. Ambiguity and insufficient coverage of the new law, improved availability of medicinal products and threats associated with data, IT systems and potentially unfavourable new reimbursement schemes were identified as key topics of each of the said top categories, respectively. Among individual sets of respondents, there is frequent consensus on both opportunities and threats in the area of implementing process changes in PB-MEA. For the successful implementation of the law in practice, some basic threats need to be removed, among which in particular is insufficient data infrastructure.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23009954
003      
CZ-PrNML
005      
20230721095403.0
007      
ta
008      
230707s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/healthcare11081179 $2 doi
035    __
$a (PubMed)37108013
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Hospodková, Petra $u Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, 272 01 Kladno, Czech Republic $1 https://orcid.org/0000000165428196
245    10
$a Opportunities and Threats of the Legally Facilitated Performance-Based Managed Entry Agreements in Slovakia: The Early-Adoption Perspective / $c P. Hospodková, K. Gilíková, M. Barták, E. Marušáková, A. Tichopád
520    9_
$a Slovakia has adopted an amendment to Act No. 363/2011, regulating, among other things, drug reimbursement and is undergoing a significant change in the availability of innovative treatments for patients. High expectations are associated with arrangements related to performance-based managed entry agreements. Opinions and positions towards this change appear to be inconsistent, and for the further application of the law in practice and when setting up the main implementation processes, it is necessary to understand the positions and opinions of the individual actors who are involved in the PB-MEA process. The interviews were conducted in the period from 20 May to 15 August 2022 around the same time as the finalisation of the amendment to Act No. 363/2011 and its adoption. A roughly one-hour open interview was conducted on a sample of 12 stakeholders in the following groups: representatives of the Ministry of Health, health-care providers, pharmaceutical companies and others, including a health insurance company. The main objective was to qualitatively describe the perception of this topic by key stakeholders in Slovakia. The responses were analysed using MAXQDATA 2022 software to obtain codes associated with key expressions. We identified three main strong top categories of expressions that strongly dominated the pro-management interviews with stakeholders: legislation, opportunities and threats. Ambiguity and insufficient coverage of the new law, improved availability of medicinal products and threats associated with data, IT systems and potentially unfavourable new reimbursement schemes were identified as key topics of each of the said top categories, respectively. Among individual sets of respondents, there is frequent consensus on both opportunities and threats in the area of implementing process changes in PB-MEA. For the successful implementation of the law in practice, some basic threats need to be removed, among which in particular is insufficient data infrastructure.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Gilíková, Klára $u Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, 272 01 Kladno, Czech Republic $1 https://orcid.org/0000000164243819
700    1_
$a Barták, Miroslav $u Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, 272 01 Kladno, Czech Republic $1 https://orcid.org/0000000272656514
700    1_
$a Marušáková, Elena $u Department of Public Health, Faculty of Health and Social Work, Trnava University, 917 01 Trnava, Slovakia $1 https://orcid.org/0009000544249849
700    1_
$a Tichopád, Aleš $u Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, 272 01 Kladno, Czech Republic $1 https://orcid.org/0000000213080877
773    0_
$w MED00200150 $t Healthcare (Basel, Switzerland) $x 2227-9032 $g Roč. 11, č. 8 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37108013 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230707 $b ABA008
991    __
$a 20230721095356 $b ABA008
999    __
$a ok $b bmc $g 1958577 $s 1196218
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 11 $c 8 $e 20230419 $i 2227-9032 $m Healthcare $n Healthcare (Basel) $x MED00200150
GRA    __
$a SGS23/197/OHK5/3T/17 $p Czech Technical University in Prague
LZP    __
$a Pubmed-20230707

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...